Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia

Peer Review reports

Original Submission
2 Oct 2013	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
22 Oct 2013	Reviewed	Reviewer Report - Wilhelm Schulte-Mattler
12 Nov 2013	Author responded	Author comments - Joanna Zakrzewska
Resubmission - Version 3
12 Nov 2013	Submitted	Manuscript version 3
Publishing
13 Nov 2013	Editorially accepted
23 Nov 2013	Article published	10.1186/1745-6215-14-402

Back to article page